Advertising and commercially sponsored publications are separate from editorial decisions. The Astha Technologies does not endorse any product or service displayed as an advertisement or promoted by a sponsor in its publications. There are no commercial or financial interests or any specific arrangements with advertising clients or sponsors that compromise editorial content.
The Astha Technologies network reserves the right to decline any type of advertising that damages the Astha Technologies brand or is inappropriate for its content.
Advertisements may not be deceptive or misleading, and must be verifiable. They must clearly identify the advertiser and the product or service they are promoting. Exaggerated or extravagant copy is not permitted. Neither text nor artwork will be accepted if they contain indecent or offensive content, or if they deal with personal, racial, ethnic, sexual orientation, or religious content.
If the Editor(s)-in-Chief or Publisher request its removal, an advertisement can be withdrawn from the journal site at any time. Astha Technologies prohibits any advertising campaign that targets a particular article or page related to the advertised treatment or drug. Advertisers are not permitted to use specific keywords to link to articles, target their product advertisement with a specific article, or reference an article that coincides with the timing of their advertisement.
All drug-specific advertisements must adhere to both European and UK laws governing advertising. The MHRA website offers up-to-date legislation and best practice guidelines for reference. When submitting advertisements, advertisers are required to provide the marketing authorization and summary of product characteristics to Astha Technologies. For drug campaigns, the complete generic name of each active ingredient must be included. Any pages within the advertisement promoting prescription-only medicines should be clearly marked as intended for healthcare professionals.
Ads for drug-specific campaigns should encourage correct and rational use and should not be misleading.
It is important to distinguish between advertisements and editorial content. Astha Technologies does not publish “advertorial” content, and sponsored supplements must be clearly indicated as such. Explicitly state if a supplement was not peer reviewed or if it went through a peer review process different from the rest of the journal.
In addition to not being influenced by current and potential sponsors and advertisers, editorial decisions will also not be influenced by marketing strategies. Searches conducted by keywords or search topics on the website are not controlled or influenced by advertisers and sponsors.
Any advertisement outside of Astha Technologies’s standard advertising positions should be submitted to editorial, who will respond with a full and final decision within two business days.
The Advertisements page will include information about complaints concerning advertisements.
We collaborate with third-party advertising businesses to display ads and gather some data when you browse our site. These entities may utilize cookies or web beacons to obtain non-personally identifiable information [excluding your name, address, email address, or phone number] while you are on our website. This assists in displaying relevant ads on other websites that may also pique your interest. To find out more about this type of advertising or to opt-out of sharing your anonymous data, please visit this link.
Policy on advertising complaints
Any complaints about advertising should be sent to ethanoliver167@gmail.com.
ASA (Advertising Standards Authority)
In addition to investigating complaints about published medicines advertisements, the Advertising Standards Authority ensures compliance with the Indian Codes of Advertising and Sales Promotion, which include a section on advertising for medicines. As well as monitoring advertising in the press, direct marketing, and sales promotion, it also monitors ads on the Internet.
PMCPA (Prescription Medicines Code of Practice Authority)
The Prescription Medicines Code of Practice Authority handles grievances regarding the advertising of prescription medicines, in accordance with the ABPI Code of Practice for the Pharmaceutical Industry. The Code of Practice Panel is responsible for addressing complaints about promotional activities and materials, and their decisions can be appealed to the Code of Practice Appeal Board. Quarterly updates on resolved cases are released in the form of the Code of Practice Review.